Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Completed · Phase 3 · Has a placebo group

Conditions studied: Polycythemia Vera

In brief

The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.

Key facts

Study ID

NCT01632904

Run by

Incyte Corporation

People needed

110

Starts

2012-06-01

Expected to finish

2016-05-01

Last updated by the study team

2017-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must currently be reporting symptoms while on a stable dose of HU monotherapy and be eligible to continue HU on study after randomization.
• Before screening, the subject must have been receiving HU for at least 12 weeks AND be receiving a stable dose.
• Subjects must meet baseline symptom criteria
• Subjects should meet at least 1 of the following criteria:
• No more than 2 phlebotomies within the 6 months before screening OR
• No palpable splenomegaly.
• Subjects must have a hematocrit that can be controlled within 35% to 48% (inclusive) before randomization.

You may not qualify if…

• Subjects with inadequate liver or renal function at screening.
• Subjects with clinically significant infection that requires therapy
• Subjects with known active hepatitis A, B, or C at screening or with known HIV positivity.
• Subjects with an active malignancy over the previous 2 years
• Subjects with clinically significant cardiac disease (Class III or IV).

Where it is running

• Study site — Fayetteville, Arkansas, United States
• Study site — Burbank, California, United States
• Study site — Glendale, California, United States
• Study site — La Jolla, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Diego, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Stamford, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Niles, Illinois, United States
• Study site — Springfield, Illinois, United States
• Study site — Ames, Iowa, United States
• Study site — Westwood, Kansas, United States
• Study site — Alexandria, Louisiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Southfield, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Columbia, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Henderson, Nevada, United States
• Study site — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.